By Matthew Bultman (January 11, 2019, 6:14 PM EST) -- The Patent Trial and Appeal Board dipped its toe into the pool of marijuana-related inventions with a recent decision involving an epilepsy treatment patent, providing the cannabis industry a glimpse at what to expect in America Invents Act reviews.
The PTAB's decision, issued Jan. 3, came in an inter partes review Insys Development Co. Inc. brought against a patent belonging to a unit of GW Pharmaceuticals PLC, a U.K. company known for its marijuana-derived medicines. The board invalidated two patent claims but upheld several others.
Insys' challenge was believed to be the first to a cannabis-related patent in AIA review by...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!